Table 2.
Components | Serum Dilutions | Control | Geometric Average Titer of Neutralizing Antibodies Log2 | |||||||
---|---|---|---|---|---|---|---|---|---|---|
1:2 | 1:4 | 1:8 | 1:16 | 1:32 | 1:64 | Virus (100 TCD50) + Medium | Serum 1:2 + Medium | medium | ||
Serum to the protein SPPV060 + virus (100 TCD50) | - - - - | - - - - | - - - - | - + + + | + + + + | + + + + | + + + + | - - - - | - - - - | 3.75 |
Serum to the protein SPPV095 + virus (100 TCD50) | + + + + | + + + + | + + + + | + + + + | + + + + | + + + + | + + + + | - - - - | - - - - | 0.0 |
Serum to the protein SPPV117 + virus (100 TCD50) | - - - - | - - - - | - - - - | - - + + | + + + + | + + + + | + + + + | - - - - | - - - - | 4.0 |
Serum to the protein SPPV122 + virus (100 TCD50) | - - - - | - - - - | - - - - | + + + + | + + + + | + + + + | + + + + | - - - - | - - - - | 3.5 |
“+”, the presence of CPE in well; “-“, the absence of CPE in well.